All these medical indices are important factors for early prediction of DFU. Current medical approaches are i) invasive (e.g., skin lesion biopsy), ii) requires consumables, and iii) being operated by certified physicians (e.g., ultrasound and/or biopsy). PHOOTONICS aims at developing a non-invasive, reliable and cost-effective photonics-driven device for DFU monitoring and management which can be applied for wide use. The project supports two versions: (i) the PHOOTONICS In-Home, used for DFU monitoring by patients and (ii) the PHOOTONICS PRO operated by physicians.

Reliability is achieved by optimizing i) passive Hyperspectral (HIS) NIR photo-detector, with an active tuneable diode illuminator for detecting SpO2/StO2, HbO2 and Hb, ii) a thermal-IR sensor of detecting hyperthermia/hypothermia distributions in ROIs and iii) a passive Mid-IR sensing with a Quantum Cascade Laser (QCL) optimized to capture additional tissue attributes such as proteomics (elastin, collagen) and metabolomics (glucose). Cost-effectiveness is achieved by introducing i) targeted photonics technologies for DFU, ii) implementing advanced signal processing/learning algorithms to increase the discrimination accuracy while maintaining hardware cost-benefit, (iii) developing a user-friendly framework operated by non-certified physicians, and even by patients (for the In-Home version), and (iv) minimising operational cost with our non-invasive device. Clinical studies are performed to validate the reliability of the new cost-effective device in real-life settings.